Alloplastic injectable dermal filler and methods of use thereof

Abstract

A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent.

1 - 31 . (canceled) 
     
     
         32 . A composition comprising:
 an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent;
 wherein the biocompatible and pliable material is a copolymer of phenylethyl acrylate and phenylethyl methacrylate; and 
 wherein said copolymer is a solid. 
   
     
     
         33 . The composition of  claim 32 , wherein the solid copolymer is a powder, a non-porous microbead, or a microsphere. 
     
     
         34 . The composition of  claim 32 , wherein the solid copolymer comprises particles each having a diameter of about 10μ to about 100μ; about 0.01μ to about 10μ; or about 0.01μ to about 5μ. 
     
     
         35 . The composition of  claim 32 , wherein the physiologically acceptable suspending agent is resorbable. 
     
     
         36 . The composition of  claim 35 , wherein the physiologically acceptable suspending agen s a buffered physiological solution, cross-linked sodium hyaluronate, a non cross-linked sodium hyaluronate, isolated collagen, collagen isolated from an animal, collagen isolated from a bird, or genetically engineered collagen. 
     
     
         37 . The composition of  claim 32 , wherein said composition further comprises a local anesthetic. 
     
     
         38 . The composition of  claim 32 , wherein the phenylethyl acrylate and the phenylethyl methacrylate are present in the copolymer at a molar ratio of about 1:1000; about 1:100; about 1:10; about 1:9; about 1:8; about 1:7; about 1:6; about 1:5; about 1:4; about 1:3; about 1:2; or about 1:1. 
     
     
         39 . The composition of  claim 32 , wherein said copolymer is cross-linked with 1.4 butanediol diacrylate. 
     
     
         40 . A method of making the composition of claim  1  comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent;
 wherein the biocompatible and pliable material is a copolymer of phenylethyl acrylate and phenylethyl methacrylate; and 
 wherein said copolymer is a solid. 
 
     
     
         41 . The method of  claim 40 , wherein said copolymer is cross-linked with 1.4 butanediol diacrylate. 
     
     
         42 . A method of augmenting soft tissue to provide long-term reduction of a skin defect comprising injecting into the deep reticular dermis the composition of claim  1 . 
     
     
         43 . The method of  claim 42 , wherein the dynamic wrinkle is a forehead crease, a brow burrow or an eye line (crow's feet). 
     
     
         44 . The method of  claim 43 , wherein the static wrinkle is a skin fold wrinkle resulting from sagging skin. 
     
     
         45 . The method of  claim 42 , wherein the long-term reduction of the skin defect is of a duration of at least one year. 
     
     
         46 . The method of  claim 42 , wherein the long-term reduction of the skin defect is of a duration of from at least one year to about five years. 
     
     
         47 . The method of  claim 42 , wherein the long-term reduction of the skin defect is of a duration from about five years to about ten years. 
     
     
         48 . The method of  claim 42 , wherein the long-term reduction of the skin defect is of a duration from about ten years or longer.